| Molecular Formula | C10H8N6O |
| Molar Mass | 228.21 |
| Density | 1?+-.0.1 g/cm3(Predicted) |
| Melting Point | 310-311° (dec) |
| Boling Point | 454.8±55.0 °C(Predicted) |
| pKa | 4.00±0.50(Predicted) |
| Physical and Chemical Properties | Crystallized from dimethylformamide, melting point 310-311 ℃ (decomposition). Pemirolast Potassium (Pemirolast Potassium):C10H7N6OK. [100299-08-9]. Pale yellow crystalline powder, odorless, bitter taste. Easily soluble in water, hardly soluble in methanol or ethanol. Several insoluble in ether. Melting point> 320 ℃. |
| overview | pemiroxast can strongly inhibit extracellular calcium influx and intracellular calcium release, inhibit phosphodiesterase activity, increase intracellular cAMP level, and also inhibit arachidonic acid release and metabolism. It has an inhibitory effect on the release of histamine, leukotriene, prostaglandin, etc. caused by antigen-antibody reaction, and reduces passive skin allergic reactions and experimental asthma. It is clinically used to prevent or reduce the attack of bronchial asthma, and cannot quickly relieve the attack of acute asthma. Oral, 10mg each time, 2 times a day, morning, afternoon or before going to bed. Adverse reactions and precautions: occasional headache, stomach discomfort, constipation, dry mouth, rash, itching, etc., increased platelet count, liver and kidney damage, etc. Use with caution for breastfeeding women and young children. |
| use | for bronchial asthma. |
| Production method | 2-amino-3-methylpyridine and sodium azide, aluminum trichloride and 3-ethoxy-2-cyanoacrylate Ethyl is refluxed in tetrahydrofuran to obtain pimillast. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |